Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system

Clinical Infectious Diseases

Volumn 53, Issue 9, 2011, Pages 879-884

  Pogue, Jason M ^a,b   Lee, Jiha ^b   Marchaim, Dror ^b,c   Yee, Victoria ^b   Zhao, Jing J ^d   Chopra, Teena ^b,c   Lephart, Paul ^e   Kaye, Keith S ^b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Division of Internal Medicine   (United States)

^d HARPER UNIVERSITY HOSPITAL   (United States)

^e DETROIT MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; CREATININE; RIFAMPICIN;

ADULT; ARTICLE; BODY WEIGHT; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH CARE SYSTEM; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COLISTIN; FEMALE; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 80054088449     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir611     Document Type: Article

References (21)

1. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10:R27.
2. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort of 258 patients. Int J Antimicrob Agents 2010; 35:194-9.
3. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010; 65:1019-27.
4. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7:R78-83.
5. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11:115-21. (Pubitemid 40259694)
6. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49:3136-46. (Pubitemid 41060551)
7. Kaye KS, Kaye D. Polymyxins (polymyxin B and colistin). In Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases 6th ed. Philadelphia, PA: Elsevier Inc., 2005; 435-6.
8. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48:1724-8.
9. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract 2008; 109:c182-7.
10. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008; 30:143-51. (Pubitemid 351834728)
11. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430-6.
12. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-94.
13. FalagasME, RizosM, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005; 5:1.
14. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54:4503-5.
15. De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lameire NH. Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis 1998; 31: 108-15. (Pubitemid 28116691)
16. Wiggins KJ, Galanos JW, Hill PA, Scott KV, Langham RG. Rifampicinassociated segmental necrotizing glomerulonephritis in staphylococcal endocarditis. J Nephrol 2007; 20:489-94. (Pubitemid 350081505)
17. Muthukumar T, Jayakumar M, Fernando EM, Muthusethupathi MA. Acute renal failure due to rifampicin: a study of 25 patients. Am J Kidney Dis 2002; 40:690-6.
18. Ku K, Pogue JM, Moshos J, et al. Colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem resistant Enterobacteriaceae infections [abstract 4282]. In: Presented at the Society for Healthcare Epidemiology of America (SHEA) 21st Annual Meeting. Dallas, TX, 2011.
19. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health-care associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29:1107-15. (Pubitemid 47208584)
20. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008; 62:168-71. (Pubitemid 351865892)
21. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-6. (Pubitemid 351521995)